|
There are a number of conflicting articles out there about which is harder to cure - primary or secondary mds or aml. Just this morning I read several articles (dates are important) that have started performing analyses that separate out the different variables.
Bottom line here is that most of the recent work done suggests that it really comes back to number and type of chromosomal abnormalities and overall health status (existing comorbidities). Whether it is primary or secondary or therapy related seems to be less relevant to the outcome. The historical context is that T-MDS/AML or S-MDS/AML patients typically have more or worse chromosomal abnormalities than deNovo.
I hope that helps, and good luck on the next steps, keep pushing for a good answer.
__________________
MDS RCMD w/grade 2-3 fibrosis. Allo-MUD Feb 26, 2014. Relapsed August 2014. Free and clear of MDS since November 2014 after treatment with Vidaza and Rituxan. Experiencing autoimmune attack on CNS thought to be GVHD, some gut, skin and ocular cGVHD. Neuropathy over 80% of body.
|